|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Distribuirea grasimii corporale - Waist-to-Hip-Ratio (WHR)Cu cit este mai mare BMI cu atit riscul de infarct miocardic si accident vascular cerebral creste. Studiile internationale arata ca factorul de risc = distribuirea grasimii corporale - Waist-to-hip-Ratio (WHT) care este o mai buna masurare a riscului de infarct si accident vascular cerebral. La barbati: distribuirea grasimii corporale regiunea abdomenului, (forma de mar) cu un risc marit de boli cardiovasculare
La femei: distribuirea grasimii corporale pe fese si coapse - obezitate gluteo-femurala, (forma de para) cu un risc marit de boli cardiovasculare Pentru distribuirea grasimii corporale (WHR) se caracerizeaza = Raportul dintre Distribuirea grasimii corporale a taliei si distribuirea grasimii corporale a soldului - La barbati: WHR este mai mare de 1 = forma de mar - La femei: WHR este mai mare de 0,85 = forma de para - Riscul circumferintei abdominale incepe la barbati cu talia de 94 cm, iar la 102 cm se afla in zona de pericol, cu marirea valorilor de trigliceride, si cresterea colesterolului in singe, care sint facori de risc, infarct miocardic si accident vascular cerebral
- Riscul circumferintei abdominale incepe la femei cu talia de 80 cm, iar la 88 cm se afla in zona de pericol, cu marirea valorilor de trigliceride, si cresterea colesterolului in singe, care sint facori de risc, infarct miocardic si accident vascular cerebral
Reducerea de: Hemoglobina glicozilata HbA1cTesutul adipos secreta: Citokine (Mediatori inflamatorii), un factor implicat in procesul de ateroscleroza ca factor de agregare plachetara, factor regulator al tensiunii si factor regulator al metabolizmului cu hormonul: Adiponectina un factor protector cardiovascular si un biomarker de risc.Cu aparatul de masura a greutatii corporale si circumferinta abdominala se constata riscul bolilor metabolice: diabet zaharat tip 2, afectiuni cardiovasculare si accident vascular cerebral, recomandabil: Vitamina E Forte 400 UI.La barbati cine are indexul masei corporale BMI mai mare de 30 kg/m2(Biomarker de sindrom metabolic) si o circumferinta abdominala mai mare de 102 cm este afectat grav.La femei riscul creste deja la o circumferinta abdominala de 88 cm este afectat grav de a primi boli metabolice: diabet zaharat tip 2, afectiuni cardiovasculare si accident vascular cerebral, recomandabil: Vitamina E Forte 400 UI.Cu 4 ore de sport, pe saptamina si un consum zilnic mai mic de 30 % de acizi grasi, dintre care acizi grasi saturati mai putin de 10 % si 15 g/1000kcal-fibra dietetica (dietary fiber), recomandabil: Chitosan Plus, Cura de Slabire si
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Super Chitosan Plus 1 Caps. cu: L-Carnitina Pura de (Baza) 235 mg, Chitosan 100 mg de la LipoSan Ultra, Psyillium Husk 100 mg, Pectina din Mere 100 mg, Guar Gum 100 mg, Guarana (Paullinia cupana) 50 mg, Ceai Verde Supreme EGCG 50% 50 mg, Gymnema Sylvestre 15 mg
= 0,72 lei
noi/zi
prin: Oferta speciala!
| Tesut adipos inainte de cura de slabire | Tesut adipos dupa cura de slabire |
 |
 |
- Cercetatori de la Institutul Francez INSERM au publicat
in revista „Cell Metabolism “ au explicat cum proteinele reduce
apetitul, si foamea.
- Cercetatorii Francezi au constatat o alimentatie bogata in proteine, da semnalul
activitatii genetice de crestere a glucozei pe care ficatul trimete semnalul
catre cerebral de stopare alimentara.
- Cecetatorul Gilles Mithieux presupune eliberarea substanzei ciclice AMP care
activeaza gena de producere a glucozei.
Un studiu stiintific cu Christian Roberts de la Universitatea din California arata ca in numai trei saptamini se inbunatateste valorile sanatatii, la 31 de barbati cu obezitate severa:
Majoritatea obezilor sufera de sindrom metabolic, hipertensiune arteriala, valorile de colesterol inalte, dezechilibru glucozic, creste numarul de cazuri cu diabet tib 2.
- Schimbarea regimului alimentar, reducere calorica, cu fibre dietetice, program sportiv de 45 min. - 60 min.
- La ateroscleroza regimul alimentar si programul sportiv trebuie prelungit pe lunga durata.
| Bibliografie-Referinte: |
 |
1. Girola M, De Bernardi M, Contos S et al: Dose effect in lipid-lowering
activity of a new dietary integrator (chitosan, Garcinia cambogia extract and
chrome).
Acta Toxicol Ther 1996; 17(1):25-40.
- Zahorska-Markiewicz B, Krotkiewski M, Olszanecka-Glinianowicz M, Zurakowski
A. Effect of chitosan in complex management of obesity. Pol Merkuriusz Lek
2002;13:129–32
- "A non-prescription alternative in weight reduction therapy " Conte
AA. Am J Bariatr Med. Summer 1993:17-19
- Dietary Supplements and Functional Foods; July 11, 1995; Las Vegas, NV.
2. Schiller RN et al. A randomized, double
blind, placebo-controlled study examining the effects of a rapidly soluble chitosan
dietary supplement on weight loss and body composition in overweight and mildly
obese individuals. JANA. 4(1):42-9, 2001.
3. Pittler MH, Abbot NC, Harkness EF, Ernst
E. Randomized,
double-blind trial
of chitosan for body weight reduction. Department of Complementary Medicine,
School of Postgraduate Medicine and Health Sciences, University of Exeter, United
Kingdom. Eur J Clin Nutr. 1999 May;53(5):379-81.
4. Kanauchi O, Deuchi K, Imasato Y, Shizukuishi
M, Kobayashi E.
Mechanism
for the inhibition of fat digestion by chitosan and for the synergistic effect
of ascorbate. Biosci Biotechnol Biochem. 1995 May;59(5):786-90.
- Nauss J L, et al, "The Binding of Micellar lipids to Chitosan," Lipids
18 (10). 1983. 714-719 Chitosan absorbs 4-6 times its own weight in fat
- Nauss JL, Thomson JL, Nagyuvary Y et al. The binding of micellar lipids to
chitosan. Lipids. 1983; 18:246-7.
- Deuchi K, Kanauchi O, Imasato Y, et al. Decreasing effect of chitosan on the
apparent fat digestibility by rats fed on a high-fat diet. Biosci Biotech Biochem
1994;58:1613–6.
- Kanauchi O, Deuchi K, Imasato Y, et al. Increasing effect of a chitosan and
ascorbic acid mixture on fecal dietary fat excretion. Biosci Biotech Biochem
1994;58:1617–20.
5. Sakkinen M, Marvola J, Kanerva H,
Lindevall K, Lipponen M, Kekki T, Ahonen A, Marvola M. Gamma
scintigraphic evaluation of the fate of microcrystalline chitosan granules
in human stomach. Division of Biopharmaceutics and Pharmacokinetics,
Department of Pharmacy, University of Helsinki, Helsinki, Finland. mia.sakkinen@helsinki.fi
Eur J Pharm Biopharm. 2004 Jan;57(1):133-43.
6. Colombo P, Sciutto AM. Nutritional
aspects of chitosan employment in hypocaloric diet. Acta Toxicol Ther. 1996;
16:287-302.
7. Sciutto AM, Colombo P. Lipid-lowering
effect of chitosan dietary integrator and hypocaloric diet in obese subjects.
Acta Toxicol Ther. 1995; 16:215-30.
8. Razdan, A., et al., "Broiler chicken
body weights, feed intakes, plasma lipid and small-intestinal bile acid concentrations
in response
to feeding of chitosan and pectin," Br J Nutr, 78(2):283-91 1997 Aug
9. Chiang, M.T., et al., "Effect
of dietary chitosans with different viscosity on plasma lipids and lipid peroxidation
in rats fed on a diet enriched with cholesterol," Biosci Biotechnol Biochem,
64(5):965-71
May 2000
10. Giustina A, Ventura P. Weight-reducing
regimens in obese subjects: effects of a new dietary fiber integrator. Acta
Toxicol Ther. 1995; 16:199-214.
11. Mattioli-Belmonte M, Muzzarelli
B, Muzzarelli RAA. Chitin and chitosan in wound healing and other biomedical
applications.
Carbohydr Eur 1997(19Dec):30-36.
- Muzzarelli RAA, Biagini G. Role and fate of exogeneous chitosans in human wound
tissues. Ed Chitin Enzymology, Eur Chitin Soc 1993, Ancona.
12. Chitin : A Natural Product for
the 21st
Century, International Commission on Natural Health Products, 1995.
- DerMarderosian A, Beutler JA, eds. Facts and comparisons: the review of natural
products. St. Louis: Wolters Kluwer;
2002.
- Borchard, G and Junginger H.E., Modern drug delivery applications of chitosan.
Adv Drug Del Rev., 52 (2): 103, 2001.
-Shigemasa Y, Minami S. Applications of chitin and chitosan for biomaterials.
Biotechnol Gen Eng Rev 1995;13:383-420.
-
Chandy, T. Sharma, C.P. "Chitosan - as a biomaterial biosurface technology
division," Sree Chita Triunal Institute for Medical Sciences and Technology,
Poojandrum, India. 1990
13. Macchi
G. A new approach to the treatment of obesity: chitosan's effect on body weight
reduction and plasma cholesterol
levels. Acta Toxicol Ther. 1996;
16:303-20.
- Zahorska-Markiewicz B, Krotkiewski M, Olszanecka-Glinianowicz M, Zurakowski
A. Effect
of chitosan in complex management of obesity Pol Merkuriusz Lek. 2002 Aug;13(74):129-32.
14. Muzzarelli
RA. Clinical and biochemical evaluation of chitosan for hypercholesterolemia
and overweight control. In: Jolles P, Muzzarelli RA, eds. Chitin and chitinases.
Basel, Switzerland: Birkhäuser; 1999:293-304.
- Tai TS, Sheu WH, Lee WJ, Yao HT, Chiang MT. Effect
of chitosan on plasma lipoprotein concentrations in type 2 diabetic subjects
with hypercholesterolemia.
Diabetes Care. 2000 Nov;23(11):1703-4.
- Ylitalo R, Lehtinen S, Wuolijoki E, Ylitalo P, Lehtimaki T Cholesterol-lowering
properties and safety of chitosan. Arzneimittelforschung 2002;52(1):1-7-2
- Lee JK, Kim SU, Kim JH. Modification
of chitosan to improve its hypocholesterolemic capacity. Biosci Biotechnol
Biochem. 1999 May;63(5):833-9.
15. Maezaki Y, Tsuji K, Nakagawa Y
et al. Hypocholesterolemic effect of chitosan
in adult males. Biosci Biotech Biochem. 1993; 57:1439-44.
16. Chitosan
for weight loss and cholesterol management. Shields KM, Smock N, McQueen
CE, Bryant PJ. Am J Health Syst Pharm. 2003 Jul 1;60(13):1310-2, 1315-6.
17. Zacour AC, Silva ME, Cecon PR, Bambirra
EA, Vieira EC. Effect
of dietary
chitin on cholesterol absorption and metabolism in rats. Departamento de
Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Brazil. J Nutr
Sci Vitaminol
(Tokyo). 1992 Dec;38(6):609-13.
18. Veneroni G, Veneroni F, Contos
S et al. Effect of a new chitosan dietary integrator and hypocaloric diet on
hyperlipidemia and overweight in obese patients. Acta
Toxicol Ther. 1996; 16:53-70
19. Dunstan DW, Daly RM, Owen N,
Jolley D, De Courten M, Shaw J, Zimmet P. High-intensity resistance training
improves glycemic
control in older patients with type 2
diabetes. Diabetes Care. 2002; (10): 1729-36.
20. Jakicic JM, Marcus BH, Gallagher
KI, Napolitano M, Lang W. Effect of exercise duration and intensity on weight
loss in overweight, sedentary women: a randomized
trial. JAMA. 2003; 290(10): 1323-30.
21. Slentz CA, Duscha BD, Johnson
JL, Ketchum K, Aiken LB, Samsa GP, Houmard JA, Bales CW, Kraus WE. Effects
of the
amount of exercise on body weight, body composition, and measures of central
obesity: STRRIDE--a randomized controlled study. Arch Intern Med. 2004; 164(1):
31-9.
22. Lafortuna CL, Resnik M, Galvani
C, Sartorio A. Effects of non-specific vs individualized exercise-training
protocols on aerobic, anaerobic and strength
performance in severely obese subjects during a short-term body mass reduction
program. J Endocrinol
Invest. 2003; 26(3): 197-205.
23. Kim KW, Thomas RL, Lee C, Park
HJ. Antimicrobial
activity of native chitosan, degraded chitosan, and O-carboxymethylated chitosan.
J Food Prot. 2003 Aug;66(8):1495-8.
-
Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. Immunological
activity of chitin and its derivatives. Vaccine 1984;2:93-99.
- Choi BK, Kim KY, Yoo YJ, Oh SJ, Choi JH, Kim CY. In vitro antimicrobial activity
of a chitooligosaccharide mixture against Actinobacillus actinomycetemcomitans
and Streptococcus mutans. Int J Antimicrob Agents 2001;18:553-557
- Zochina, Z.M. et al. "Inhibition of Chitosan of infection of t-series
bacteriophages in the escherichia coli," Mikrobiologia, 1995 March/April:
64 (2) 211-5
- Tsai GJ, Zhang SL, Shieh PL. Antimicrobial
activity of a low-molecular-weight chitosan obtained from cellulase digestion
of chitosan. J Food Prot. 2004 Feb;67(2):396-8.
- Zivanovic S, Basurto CC,
Chi S, Davidson PM, Weiss J. Molecular
weight of chitosan influences antimicrobial activity in oil-in-water emulsions.
J Food Prot. 2004 May;67(5):952-9.
- Choi BK, Kim KY, Yoo YJ, Oh SJ, Choi JH, Kim CY. In vitro antimicrobial activity
of a chitooligosaccharide mixture against Actinobacillus actinomycetemcomitans
and Streptococcus mutans. Int J Antimicrob Agents 2001;18:553-557
24. Fujiwara M, Hayashi Y, Ohara
N. Inhibitory
effect of water-soluble chitosan on growth of Streptococcus mutans. New
Microbiol.
2004 Jan;27(1):83-6.
25. Jing SB, Li L, Ji D, Takiguchi
Y, Yamaguchi T. Effect
of chitosan on renal function in patients with chronic renal failure.
J Pharm Pharmacol. 1997 Jul;49(7):721-3.
26. Davidson MH, Dugan LD, Burns JH,
et
al. A
psyllium-enriched cereal for the treatment of hypercholesterolemia in children:
A controlled, double-blind, crossover study. Am J Clin Nutr 1996;63:96-102.
27. Anderson JW, Allgood LD, Lawrence
A, et al. Cholesterol-lowering
effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia:
meta-analysis of 8 controlled trials. Am J Clin Nutr 2000;71:472–9.
- Anderson JW, Davidson MH, Blonde L, et al. Long-term cholesterol-lowering effects
as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J
Clin Nutr 2000;71:1433-8.
28. Oson BH, Anderson SM, Becker MP,
et al. Psyllium-enriched
cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol,
in hypercholesterolemic adults: Results of a meta-analysis.
J Nutr 1997;127:1973-80.
29. Anderson JW, Allgood LD, Turner
J, et al. Effects of psyllium on glucose and serum lipid response in men
with type
2 diabetes and hypercholesterolemia.
Am J Clin Nutr 1999;70:466-73.
- Rodriguez-Moran M, Guerrero-Romero F, Lazcano-Burciaga G. Lipid- and glucose-lowering
efficacy of plantago psyllium in type II diabetes. J Diabetes Complications 1998;12:273-8.
30. Fernandez-Banares F, Hinojosa
J, Sanchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata
seeds
(dietary fiber) as compared with mesalamine in
maintaining remission in ulcerative colitis. Am J Gastroenterol 1999;94:427-33.
31. Miyasaka A, Imoto T. Electrophysiological
characterization of the inhibitory effect of a novel peptide gurmarin on the
sweet taste response
in rats. Brain Res. 1995 Apr 3;676(1):63-8.
- Ray A, Birch GG. Time dependent inhibition of sucrose sweetness with gymnemic
acid: mode of action. Life Sci,
1981;28:2773-2781
- Meiselman HL, Halpern BP. Effects of Gymnema sylvestre on complex tastes elicited
by amino acids and sucrose. Physiol
Behav, 1970;5:1379-1384
- Warren RP, Warren RM, Weninger MG. Inhibition of the sweet taste by Gymnema
sylvestre. Nature, 1969;223:94-95
- Kurihara Y. Antisweet activity of gymnemic acid A1 and its derivatives. Life
Sci, 1969;8:537-543
- Ota M, Shimizu Y, Tonosaki K, Ariyoshi Y. Role of hydrophobic amino acids in
gurmarin, a sweetness-suppressing polypeptide. Biopolymers. 1998 Mar;45(3):231-8.
- Ota M, Shimizu Y, Tonosaki K, Ariyoshi Y. Synthesis, characterization, and
sweetness-suppressing activities of gurmarin analogues missing one disulfide
bond. Biopolymers. 1998 Aug;46(2):65-73.
- Suttisri R, Lee IS, Kinghorn AD. Plant-derived triterpenoid sweetness inhibitors.
J Ethnopharmacol. 1995 Jun 23;47(1):9-26.
32. Shimizu K, Abe T, Nakajyo S,
Urakawa N, Atsuchi M, Yamashita C. Inhibitory effects of glucose utilization
by gymnema acids in the guinea-pig ileal longitudinal
muscle. J Smooth Muscle Res. 1996 Oct;32(5):219-28.
- Fushiki T, Kojima A, Imoto T, Inoue K, Sugimoto E. An extract of Gymnema sylvestre
leaves and purified gymnemic
acid inhibits glucose stimulated gastric inhibitory peptide secretion in rats.
J Nutr, 1992;122:2367-2373
- Shimizu K, Iino A, Nakajima J, Tanaka K, Nakajyo S, Urakawa N, Atsuchi M, Wada
T, Yamashita C. Suppression of glucose absorption by some fractions extracted
from Gymnema sylvestre leaves. J Vet Med Sci. 1997 Apr;59(4):245-51.
- Shimizu K, Ozeki M, Tanaka K, Itoh K, Nakajyo S, Urakawa N, Atsuchi M. Suppression
of glucose absorption by extracts from the leaves of Gymnema inodorum. J Vet
Med Sci. 1997 Sep;59(9):753-7.
33. Shanmugasundaram ER, Rajeswari
G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. Use
of Gymnema sylvestre leaf extract
in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol.
1990 Oct;30(3):281-94.
- Khare AK, Tondon RN, Tewari JP. Hypoglycaemic activity of an indigenous drug
(Gymnema sylvestre, 'Gurmar') in normal and diabetic persons. Indian J Physiol
Pharmacol. 1983 Jul-Sep;27(3):257-8.
34. Murakami N, Murakami T, Kadoya
M, Matsuda H, Yamahara J, Yoshikawa M. New hypoglycemic
constituents in "gymnemic acid" from Gymnema sylvestre. Chem Pharm
Bull (Tokyo). 1996 Feb;44(2):469-71.
- Chattopadhyay RR. Possible mechanism of antihyperglycemic effect of Gymnema
sylvestre leaf extract. Gen Pharmacol. 1998 Sep;31(3):495-6.
35. Srivastava Y, Nigam SK, Bhatt
HV, Verma Y, Prem AS. Hypoglycemic and life-prolonging properties of Gymnema
sylvestre leaf extract in diabetic rats. Isr J Med Sci.
1985 Jun;21(6):540-2.- Yoshikawa M, Murakami T, Kadoya M, Li Y, Murakami N, Yamahara
J, Matsuda H. Medicinal foodstuffs. IX. The inhibitors of glucose absorption
from the
leaves
of Gymnema sylvestre R. BR. (Asclepiadaceae): structures of gymnemosides a
and b. Chem Pharm Bull (Tokyo). 1997 Oct;45(10):1671-6.
- Yoshikawa M, Murakami T, Matsuda H. Medicinal foodstuffs. X. Structures of
new triterpene glycosides, gymnemosides-c, -d, -e, and -f, from the leaves of
Gymnema sylvestre R. Br.: influence of gymnema glycosides on glucose uptake in
rat small intestinal fragments. Chem Pharm Bull (Tokyo). 1997 Dec;45(12):2034-8.
36. Shanmugasundaram ER, Gopinath
KL, Radha Shanmugasundaram K, Rajendran VM. Possible regeneration of the
islets
of Langerhans in streptozotocin-diabetic
rats given Gymnema sylvestre leaf extracts. J Ethnopharmacol. 1990 Oct;30(3):265-79.
37. Landin K, Holm G, Tengborn L, Smith
U. Guar gum improves insulin sensitivity, blood lipids, blood pressure, and
fibrinolysis in healthy men. Am J Clin Nutr
1992;56:1061-5.
38. Todd PA, Befield P, Goa KL. Guar
gum: a review of its pharmacological properties and use as a dietary adjunct
in hypercholesterolemia. Drugs 1990;39:917-28.
39. Lima WP, Carnevali LC Jr, Eder R,
Costa Rosa LF, Bacchi EM, Seelaender MC. Lipid
metabolism in trained rats: effect of guarana (Paullinia cupana Mart.)
supplementation. Department of Cell and Developmental Biology, Institute
of Biomedical Sciences, Av. Prof. Lineu Prestes 1524, Sao Paulo, SP, CEP 05508-900,
Brazil.
Clin Nutr. 2005 Dec;24(6):1019-28. Epub 2005 Sep 22
40. Andersen T, Fogh J. Weight
loss and delayed gastric emptying following a South American herbal preparation
in overweight patients. Department of Ultrasound, Medical Center Charlottenlund,
Trunnevangen 4A, DK 2920, Charlottenlund, Denmark. J Hum Nutr Diet. 2001
Jun;14(3):243-50.
41. Miura T, Tatara M, Nakamura K,
Suzuki I. Effect
of guarana on exercise in
normal and epinephrine-induced glycogenolytic mice. Department of Clinical
Nutrition, Suzuka University of Medical Science, Faculty of Health Science, Mie,
Japan.
Biol Pharm Bull. 1998 Jun;21(6):646-8.
42. Basile, A., et al. “Antibacterial
and antioxidant activities of ethanol extract from Paullinia cupana Mart.” J.
Ethnopharmacol. 2005 Oct; 102(1):
32-6.
43. Dulloo AG, Duret C, Rohrer D,
et al. Efficacy
of a green tea extract rich in catechin polyphenols and caffeine in increasing
24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr.
1999;
70:1040-1045.
44. Hase, T., et al., Anti-obesity
effects of tea catechins in humans.
J Oleo Sci, 2001. 50(7): p. 599-605.
45. Tsuchida, T., H. Itakura, and
N. H., Reduction of body fat in humans by long-term ingestion of catechins.
Progress in Medicine, 2002. 9(22):
p. 2189-2203.
46. Nagao T, Komine Y, Soga S, Meguro
S, Hase T, Tanaka Y, Tokimitsu I. Ingestion
of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified
LDL in men. Health Care Products Research Laboratories No.1, Kao Corporation,
Tokyo. Am J Clin Nutr. 2005 Jan;81(1):122-9.
47. Bérubé-Parent S, Pelletier
C, Doré J, Tremblay A. Effects
of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate
and caffeine on 24 h energy expenditure and fat
oxidation in men. Division of Kinesiology, Laval University, Ste-Foy, Québec,
Canada, G1K 7P4. Br J Nutr. 2005 Sep;94(3):432-6.
- Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, Chantre P, Vandermander
J. Efficacy
of a green tea extract rich in catechin polyphenols and caffeine in increasing
24-h energy expenditure and fat oxidation in humans. Department of Physiology,
Faculty of Medicine, University of Geneva. abdul.dulloo@unifr.ch Am J Clin Nutr.
1999 Dec;70(6):1040-5.
48. Klaus S, Pültz S, Thöne-Reineke
C, Wolfram S. Epigallocatechin
gallate attenuates diet-induced obesity in mice by decreasing energy absorption
and increasing fat oxidation. Group of Energy Metabolism, German Institute
of Human Nutrition in Potsdam, Nuthetal, Germany. Int J Obes
(Lond). 2005 Jun;29(6):615-23.
49. Wolfram S, Raederstorff D, Wang
Y, Teixeira SR, Elste V, Weber P. TEAVIGO (epigallocatechin
gallate) supplementation prevents obesity in rodents by reducing adipose tissue
mass. DSM Nutritional Products Ltd, Department of Human Nutrition and Health,
Basel, Switzerland. Ann Nutr Metab. 2005 Jan-Feb;49(1):54-63. Epub 2005 Feb
25.
50. Maebashi M, Kawamura N, Sato M,
et al. Lipid-lowering effects of carnitine in patients with type-IV hypolipoproteinaemia.
Lancet. 1978; 2:805-807.
- Rossi CS, Siliprandi N. Effects of carnitine on serum HDL-cholesterol: report
of two cases. Johns Hopkins Medical J. 1982; 150:51-54.
51. Ibrahim WH, Bailey N, Sunvold
GD, Bruckner GG. Effects
of carnitine and taurine on fatty acid metabolism and lipid accumulation in
the liver of cats
during weight gain and weight loss. Department of Clinical Sciences/Clinical
Nutrition, College of Health Sciences, University of Kentucky, Lexington, KY
40536, USA. Am J Vet Res. 2003 Oct;64(10):1265-77.
52. Vacha GM, Giorcelli G, Siliprandi
N, Corsi G. Favorable effects of L-carnitine treatment on hypertriglyceridemia
in hemodialysis patients: decisive role of
low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr. 1983; 38:532-540.
53. Pola P, Savi L Grilli M, et al.
Carnitine in the therapy of dyslipidemic patients. Curr Therapeu Res. 1980;
27:208-216.
54. Kim MS, Park JY, Namkoong C, Jang
PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B,
Youn JH, Lee HK, Lee KU. Anti-obesity
effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated
protein kinase. Department of Internal Medicine, University of Ulsan College
of Medicine, 138-736 Poongnap-dong, Songpa-ku, Seoul 138-736, Korea.
55. Scholich
H, Murphy ME, Sies H. Antioxidant activity of dihydrolipoate against microsomal
lipid peroxidation
and its dependence
on alpha-tocopherol. Biochem
Biophys Acta 1989;1001:256–61.
- Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinones
in microsomes and mitochondria are mediated by tocopherol recycling. Biochem
Biophys Res Commun 1990;169:851–7.
- Busse E, Zimmer G, Schorpohl B, et al. Influence of alpha-lipoic
acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung1992;42:829–31.
56. Jacob S, Henriksen EJ, Schiemann
AL, Simon I, Clancy DE, Tritschler HJ, Jung WI, Augustin HJ, Dietze GJ. Enhancement
of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Department
of Internal Medicine, City Hospital, Baden-Baden, Germany. Arzneimittelforschung.
1995 Aug;45(8):872-4.
- Wagh SS, Natraj CV, Menon KKG. Mode of action of lipoic
acid in diabetes. J Biosci. 1987; 11:59-74.
- Jacob S Streeper RS Fogt DL Hokama JY Tritschler HJ Dietze
GJ Henriksen EJ, The antioxidant alpha-lipoic acid enhances insulin-stimulated
glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes. 1996
Aug;
45(8): 1024-9 1996 0012-1797.
- Natrej CV, Gandhi VM, Melon KKG. Lipoic acid and diabetes:
effect of dihydrolipoic acid administration in diabetic rats and rabbits. J Biosci
1984; 6:37-46.
57. "chitosan is a revolutionary
discovery that reduces fat, lowers triglycerides helps raise good cholesterol
and controls appetite naturally," says Dr.Arnold Fox, a noted Beverly Hills,
Calif., cardiologist and author of the new book: The Fat Blocker Diet, St. Martin's
Press.
58. Dr. Elizabeth Muss, assistant
clinical professor at Cornell University Medical College in Ithaca, N.Y.,
says: "chitosan is a highly effective, safe, simple, and inexpensive
way to lose fat.
|
Anti-Aging-Systeme
© 2008
|
Design by NB |